Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 6,982 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 6,982 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $26.00, for a total transaction of $181,532.00. Following the completion of the sale, the chief executive officer owned 28,523 shares in the company, valued at approximately $741,598. This trade represents a 19.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Price Performance

Shares of MAZE opened at $26.05 on Thursday. The stock has a market cap of $1.44 billion, a PE ratio of -10.30 and a beta of 2.50. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. Maze Therapeutics, Inc. has a fifty-two week low of $9.73 and a fifty-two week high of $53.65. The firm’s 50-day simple moving average is $29.69 and its two-hundred day simple moving average is $37.61.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million for the quarter. Analysts anticipate that Maze Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Maze Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in MAZE. Royal Bank of Canada boosted its holdings in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Maze Therapeutics in the fourth quarter worth approximately $39,000. Ameritas Investment Partners Inc. boosted its holdings in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Maze Therapeutics in the fourth quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. boosted its holdings in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares during the last quarter.

Analysts Set New Price Targets

MAZE has been the topic of a number of recent analyst reports. Guggenheim increased their price target on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. JPMorgan Chase & Co. increased their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Finally, Wedbush increased their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics has an average rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.